Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by princeofcuton Aug 18, 2015 3:53pm
80 Views
Post# 24029144

RE:re: Leadership Matters discussion, ETC-1002 & Don

RE:re: Leadership Matters discussion, ETC-1002 & Don
testy, thanks for the laughs i will challenge you and others with these points:

a) listen to the ESPR webcast from yesterday, their exec team killed the CC in a great way; they know their stuff inside and out and don't have to resort to Viagara jokes...the diffence in competence is clear just based on that call but wait...my 99.99% expectation is that 1002 will be approved by the FDA years before 208 ever is...and the FDA is the FDA and ain't playing favourites...and while wildly valued IMO ESPR is valued based on the confidence the market has that it will deliver the goods and RVX is based on the confidence it will not deliver the goods (ie making money)

b) Zenith was created now over 2 years ago and Zenith is still exactly the "toy" i have called it since then...this is a true statement of incompetence as with a supposed treasure trove of science nothing has happened since then of any consequence...this is a true tell

c) the incompetence IMO runs wide and deep at RVX and includes both exec and science people..the base potential of 208 seems real but IMO RVX like Zenith is a "toy" for insiders to play with
Bullboard Posts